Matek Danijel, Matek Irena, Staresinic Eva, Japjec Mladen, Bojanic Ivan, Boban Blagaic Alenka, Beketic Oreskovic Lidija, Oreskovic Ivana, Ziger Tihomil, Novinscak Tomislav, Krezic Ivan, Strbe Sanja, Drinkovic Martin, Brkic Filip, Popic Jelena, Skrtic Anita, Seiwerth Sven, Staresinic Mario, Sikiric Predrag, Brizic Ivica
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Department of Pharmacology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and Herzegovina.
Pharmaceutics. 2025 Jan 16;17(1):119. doi: 10.3390/pharmaceutics17010119.
This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration.
Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment, both complete (rectus muscle) and partial (vastus muscles).
Immediately post-injury, and at 1, 2, 3, 5, 7, 14, 21, 28, 60, and 90 days post-injury, quadriceps muscle-to-bone detachment showed definitive healing failure (impaired walking and permanent knee flexure). Contrarily, macro/microscopic, ultrasonic, magnetic resonance, biomechanical, and functional assessments revealed that BPC 157 therapy recovering effects for all time points were consistent. All parameters of the walking pattern fully improved, and soon after detachment and therapy application, muscle approached the bone, leaving a minimal gap (on ultrasonic assessment), and leg contracture was annihilated. The healing process occurs immediately after detachment from both sides: the muscle and the bone. The reattachment fibers from the ends of the muscle could be traced into the new bone formed at the surface (note, at day 3 post-detachment, increased mesenchymal cells occurred with periosteum reactivation). Consequently, at 3 months, the form was stable, and the balance between the muscle and bone was the following: well-organized bone, newly formed as more cortical bone providing a narrower bone marrow space, and the muscle and mature fibers were oriented parallel to the bone axis and were in close contact with bone.
Therefore, to achieve quadriceps muscle-to-bone reattachment, the BPC 157 therapy reversing course acts from the beginning, resolving an otherwise insurmountable deleterious course.
这是一项使用天然肽疗法的新型大鼠研究，重点是逆转股四头肌与骨的分离并实现重新附着，以及采用胃十五肽BPC 157口服疗法促进肌肉愈合和功能恢复。
药物疗法可修复各种肌肉、肌腱、韧带和骨损伤以及离断连接部位（即肌腱-肌肉连接点），特别是口服给药（BPC 157/天，10 μg/kg，10 ng/kg），在股四头肌完全离断（直肌）和部分离断（股肌）后实现肌肉与骨的重新附着。
受伤后即刻以及伤后1、2、3、5、7、14、21、28、60和90天，股四头肌与骨的分离均显示出明确的愈合失败（行走障碍和永久性膝关节屈曲）。相反，宏观/微观、超声、磁共振、生物力学和功能评估显示，BPC 157疗法在所有时间点的恢复效果都是一致的。行走模式的所有参数均得到充分改善，在离断和治疗后不久，肌肉靠近骨骼，留下极小间隙（超声评估），腿部挛缩消失。愈合过程在肌肉和骨骼两侧离断后立即发生：肌肉末端的重新附着纤维可追踪到表面新形成的骨中（注意，离断后第3天，间充质细胞增多，骨膜重新激活）。因此，在3个月时，形态稳定，肌肉与骨骼之间的平衡如下：组织良好的骨，新形成的皮质骨增多，骨髓腔变窄，肌肉和成熟纤维与骨轴平行排列并与骨紧密接触。
因此，为实现股四头肌与骨的重新附着，BPC 157疗法的逆转过程从一开始就起作用，解决了原本无法克服的有害过程。
